Venus Medtech (Hangzhou) Inc. announced unaudited consolidated earnings results for the year ended December 31, 2019. For the year, revenue was RMB 233,272,000 against RMB 115,348,000 a year ago. Loss for the year was RMB 380,765,000 against RMB 300,518,000 a year ago. Basic and diluted loss per share attributable to ordinary equity holders of the parent was RMB 1.22 against RMB 1.03 a year ago.